FDA approves AstraZeneca's Epanova, label update for Teva's Synribo; Researchers head to Twitter to identify drug problems;

> The FDA has green-lighted AstraZeneca's ($AZN) Epanova as a treatment for severe hypertriglyceridaemia in adults. Release

> The FDA has approved a label change for Teva's ($TEVA) Synribo injection that allows for home administration. Release

> A 6-week marketing suspension on Ariad's ($ARIA) chronic myeloid leukemia drug Iclusig has not negatively impacted how physicians view the drug, a survey found. More

> The U.S. diabetes market will reach $25 billion by 2020, with Sanofi ($SNY), Novo Nordisk ($NVO) and Eli Lilly ($LLY) leading the way, a new report says. Release

> An FDA panel will meet in October to review the risks of psychiatric and behavioral side effects associated with Pfizer's ($PFE) antismoking med Chantix. More

And Finally... Researchers have found that tapping into Twitter to read patient posts describing medication side effects could help them identify problems with drugs sooner. Story

Suggested Articles

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.

Lions Health shared what worked, what campaigns they wish they had created and what they’ll take back home to talk about with their colleagues.

AMAG's female libido drug Vyleesi has just won FDA approval. But will it reach blockbuster state? Management and analysts have different opinions.